Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0917801 (insomnia)
 10,606 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

We report 38 consecutive patients referred to a sleep disorder clinic who on diagnostic polysomnography showed excessive amounts of brief fragmentary myoclonus throughout all stages of NREM sleep. Almost all patients were male despite a reasonably equal sex distribution of referral. The phenomenon was found associated with sleep-related respiratory problems, periodic movements in sleep (PMS), narcolepsy, intermittent hypersomnia and (rarely) insomnia. It also occurred associated with excessive daytime sleepiness (EDS) as an isolated polysomnographic finding apart from some degree of sleep fragmentation.
 ...
PMID:Excessive fragmentary myoclonus in NREM sleep: a report of 38 cases. 241 Feb 21

Sleep disorders are becoming a major issue. Insomnia affects a substantial part of the population and may compromise individual quality of life. The principal existing hypnotic drugs, Barbiturates and Benzodiazepines are not safely. They have modes of action which results in the action of common mechanism: facilitating neurotransmission in GABAergic synapses. Stimulation of GABA receptors of the A type opens chloride ion channels which inhibits the ability of neurons to conduct nerve impulse. The clinical effects resulting which induce anticonvulsant, muscle relaxant, anxiolytic, sedative, hypnotic and amnesic effects are discussed.
 ...
PMID:[Pharmacologic aspects of sleep disorders]. 248 27

Several sleep disorders have a genetic basis. These conditions include the narcoleptic syndrome, sleep walking, periodic movements in sleep, circadian delay syndromes and familial insomnia. These disorders illustrate different control mechanisms involved in sleep and wakefulness, including those determining the prevalence and timing of NREM and REM activity, somatomotor inhibition and excitation, autonomic discharge, and the circadian framework of sleep. The genetic defect in narcolepsy has been localised to the short arm of chromosome 6, but the chromosomal localisations of the genetic basis for the other disorders are not known. Also, with the possible exception of acetylcholine, no definite neurotransmitter involved in any aspect of sleep regulation has been positively identified and the biochemical defect in narcolepsy is not known.
 ...
PMID:Genetic factors in sleep disorders. 256 31

In a double-blind cross over randomized study for the first two nights efficacy and safety of triazolam 0.25 mg and loprazolam 1 mg have been compared in 67 out-patients complaining of common insomnia and treated by general practitioners. After the second night patients had to choose one of the two treatments and were continuing a 3-week treatment period with the preferred one. In case of no preference they received one of the 2 drugs according to a new randomization. Cross over administration of the two drugs for the first two nights shows that with triazolam global help to get in sleep is greater (p = 0.016) and sleep latency is shorter (p = 0.07) than with loprazolam, and number of night awakenings is decreased (p = 0.02) compared to loprazolam. Patients felt more rested under triazolam (p = 0.015) than loprazolam. Triazolam (N = 31) is more frequently preferred than loprazolam (N = 19) p = 0.09. Preferred treatment continued to be effective during the following three weeks and quality of sleep improved drastically for all items compared to baseline data (p = 0.01). Both treatments are well tolerated (4 drop-outs for side-effects: 2 under each treatment). The one-week tapering period allows progressive withdrawal with rare reappearance of minimum sleep disorders (5 cases: 2 under triazolam, 3 under loprazolam).
 ...
PMID:[Triazolam 0.25 mg versus loprazolam 1 mg in the treatment of common insomnia treated in general practice. Double-blind cross-over randomized trial]. 256 39

Recent years have seen significant advances in sleep disorders medicine, including effective treatments for chronic psychophysiological insomnia and obstructive sleep apnea syndrome; greater understanding of biological rhythms and of the nature of sleep in depression, including seasonal affective disorder; and the discovery of REM behavior disorder. The author reviews selected developments in the sleep disorders field over the last three years. Developments are presented in the framework of the diagnostic classification of the American Sleep Disorders Association, with emphasis on areas relevant to the practice of psychiatry.
 ...
PMID:Sleep disorders: a selective update. 264 52

From 1958 to 1986, 27 crewmembers with suspected sleep disorders were referred to the USAF School of Aerospace Medicine. The presenting complaint in most cases was excessive daytime sleepiness (EDS). Prior to 1984, evaluations included neurologic and psychiatric testing, screening laboratory studies, and awake and asleep electroencephalography. Polysomnography and sleep latency studies were included after 1984. In the majority of cases, the etiology of the complaint could not be determined. The prevalence of EDS is estimated to be between 0.3% and 4.0% of the adult population. Major causes cited in the world literature include the sleep apnea syndromes, narcolepsy, parasomnias interrupting sleep, hypersomnia secondary to systemic or affective disorders, and essential hypersomnia. Current sleep lab techniques and human leukocyte antigen (HLA) typing are reported to make the diagnosis in up to 90% of sleep disorders. Evaluation of EDS should begin with a history emphasizing sleep habits, work schedules, daytime naps, and presence of vegetative signs. A sleep diary will allow a more accurate estimate of the quantity of nocturnal sleep. This diary may reveal poor sleep hygiene or insomnia. Polysomnography and/or multiple sleep latency determination can then be used to diagnose sleep apnea, parasomnias, and narcolepsy.
 ...
PMID:Evaluation of the sleepy crewmember: USAFSAM experience and a suggested clinical approach. 265 2

Sleep disorders are so common that approximately 38% of the general population complains about a current sleep problem and 52% complains about a current or past sleep problem. Psychiatric factors are prominent in virtually all sleep disorders, either as primary factors (insomnia and adult parasomnias) or as significant secondary consequences (sleep apnea and narcolepsy). The authors describe normal sleep; delineate the prevalence of sleep disorders, both those associated with psychiatric disturbance and those of organic etiology; and outline procedures for evaluation and treatment, which is multidimensional and comprises general measures, psychotherapy, and, when indicated, pharmacotherapy.
 ...
PMID:An update on sleep disorders. 265 90

Sleep apnea and PLMS are extremely prevalent in the elderly. The subjective reports of poor sleep, insomnia, snoring, and excessive daytime sleepiness should not be taken lightly and should not be assumed to be a normal sign of aging. These problems may be interrelated and may be symptoms of the sleep disorders discussed above. Physicians and gerontologists need to become more sensitive to the special problems and needs related to sleep disorders in the geriatric population.
 ...
PMID:Epidemiology of sleep disorders. 266 16

The elderly commonly complain about the quality and quantity of their sleep. The family physician can assess accurately such symptoms in the office. It is important for the physician to recognize age-related changes in sleep and obtain an accurate history. The correction of environmental disruptions and transient psycho-physiologic problems, the critical evaluation of drug use, and the treatment of underlying medical conditions are important first steps in addressing the complaint of insomnia. Appropriate sleep hygiene and pharmacologic therapy can be helpful in many instances. The family physician, however, must remember that primary sleep disorders are more common in the elderly, and sleep-center referral should be considered if such a disturbance is suspected or if problems persist after conservative therapy.
 ...
PMID:Sleep in the elderly: a practical approach. 268 23

Quazepam (QZP), a new long half-life benzodiazepine, seems to have a more specific hypnotic activity and a "physiological" mechanism of action. This study assessed its clinical efficacy and any withdrawal symptoms occurring after the treatment with QZP and triazolam (TRZ). Sixty-five patients (mean age 41.4 yrs +/- 12.43 SD) with sleep disorders were included in the study. The patients were treated with placebo for 4 days (run-in period) and if no amelioration of insomnia was observed, were then randomly allocated to 15 mg QZP (33 patients) or TRZ (32 patients) for 8 weeks and finally placebo for another week. Sleep quality, efficiency, side-effects and withdrawal effects were assessed by specific rating scales. In comparing data obtained from the two treatments, the following conclusions were drawn: 1) both drugs showed a hypnoinductive efficacy but patients treated with QZP had significantly fewer night awakenings; 2) at the end of treatment only patients treated with TRZ had longer awakenings and rebound symptoms; 3) a lower withdrawal symptom incidence was observed in patients treated with QZP. Therefore, QZP seems to have a good hypnotic effect without inducing withdrawal symptoms. In contrast TRZ turned out to be a merely hypno-inducing drug presenting higher risks of rebound effects after withdrawal.
 ...
PMID:[Controlled clinical study on the effect of quazepam versus triazolam in patients with sleep disorders]. 269 8


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>